Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Farma ondernemingen’

Alternatief voor duur medicijn taaislijmziekte op losse schroeven

De Haagse apotheker die de farmaceutische industrie wilde uitdagen door een peperduur medicijn tegen taaislijmziekte na te maken, voegt de daad voorlopig niet bij het woord. De namaakoperatie van ‘Orkambi’ is volgens hem niet noodzakelijk, omdat het ministerie van Volksgezondheid prijsafspraken heeft gemaakt met producent Vertex.    

Bron: Meer lezen »

AZ’s Fasenra approved in Europe as an add-on for severe eosinophilic asthma

AstraZeneca and its biologics R&D unit MedImmune have announced that their drug Fasenra (benralizumab) has received approval from the European Commission (EC) as an adjuvant therapy in the treatment of severe eosinophilic asthma which has been inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.

Bron: Pharmafile Meer lezen »

Pfizer stopt onderzoek neurowetenschappen

Pfizer stopt onderzoek neurowetenschappen maar creëert speciaal ondernemingsfonds Pfizer heeft bekendgemaakt haar onderzoeksprogramma’s, gericht op de ziekte van Alzheimer en Parkinson, te stoppen. Daarentegen gaat Pfizer investeren in een fonds dat bedoeld is voor biotechbedrijven die nieuw neurowetenschappelijk onderzoek willen starten.

Bron: Medicalfacts Meer lezen »

FDA clears Amgen’s bone drug for multiple myeloma

Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva (denosumab) to include the treatment of multiple myeloma, adding to its previous indication for the prevention of skeletal-related events in patients with bone metastases from solid tumours.

Bron: Pharmafile Meer lezen »

Novo Nordisk ups acquisition bid to €2.6 billion, Ablynx says no

It has emerged that Novo Nordisk has extended a bid of €2.6 billion to buy Belgian biotech Ablynx. The new offer comes in at €28 per share and is 14% higher than the one the company made on 22 December – a bid which Ablynx rejected. The deal also included an additional €2.50 per share […]

Bron: Pharmafile Meer lezen »

Pfizer exits neuroscience R&D space

Pfizer announced over the weekend that it would be backing out of research and development into the neuroscience area, abandoning a number of Phase 1 and 2 projects and removing a number of positions from the company.

Bron: Pharmafile Meer lezen »

CMS to cover Abbott’s glucose monitoring device

Abbott Laboratories said on Thursday its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States.

Bron: Reuters Meer lezen »

Philippines fines Sanofi, suspends clearance for Dengvaxia

The Philippines has suspended clearance for Sanofi’s dengue vaccine Dengvaxia and fined the French drugmaker a symbolic $2,000 citing violations on product registration and marketing, the health secretary said on Thursday.

Bron: Reuters Meer lezen »

Syntimmune brings in new CEO from Biogen

Syntimmune has revealed that it has brought in a new CEO to begin the new year, with the appointment of Jean-Paul Kress. He leaves behind his position as EVP, President International and Head of Global Therapeutic Operations at Biogen, after only eight months in the position, to take the helm.

Bron: Pharmafile Meer lezen »

Allergan to axe over 1,000 positions in cost cutting measures

Allergan was never far away from the headlines in 2017, particularly when it came to its second highest selling product, Restasis.  

Bron: Pharmafile Meer lezen »

« Oudere artikelen |